11,664 Boston Scientific Corporation $BSX Shares Bought by Krilogy Financial LLC

Krilogy Financial LLC lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 45.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 37,283 shares of the medical equipment provider’s stock after acquiring an additional 11,664 shares during the period. Krilogy Financial LLC’s holdings in Boston Scientific were worth $1,627,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in BSX. Perigon Wealth Management LLC purchased a new stake in shares of Boston Scientific in the second quarter valued at $883,000. Y Intercept Hong Kong Ltd increased its stake in Boston Scientific by 148.8% in the second quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after purchasing an additional 670,060 shares during the last quarter. Wealthfront Advisers LLC purchased a new position in Boston Scientific during the second quarter worth about $3,253,000. PensionDanmark Pensionsforsikringsaktieselskab lifted its position in Boston Scientific by 9.9% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after buying an additional 28,961 shares during the period. Finally, Tocqueville Asset Management L.P. acquired a new stake in Boston Scientific in the 2nd quarter worth about $38,539,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Boston Scientific stock opened at $44.17 on Friday. The stock’s 50-day moving average is $46.16 and its 200-day moving average is $49.80. The company has a market cap of $64.02 billion, a price-to-earnings ratio of 17.88, a price-to-earnings-growth ratio of 1.04 and a beta of 0.58. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 12 month low of $41.38 and a 12 month high of $105.65.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the previous year, the company posted $0.75 EPS. The company’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 3.24 earnings per share for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael Mahoney purchased 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David Habiger acquired 2,100 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have acquired 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on BSX shares. Barclays upgraded Boston Scientific to a “hold” rating in a report on Wednesday, October 7th. The Goldman Sachs Group cut their price objective on shares of Boston Scientific from $71.00 to $57.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. Canaccord Genuity Group decreased their target price on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Jefferies Financial Group decreased their target price on shares of Boston Scientific from $67.00 to $60.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Finally, Oppenheimer lowered their target price on shares of Boston Scientific from $85.00 to $65.00 and set an “outperform” rating for the company in a report on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $68.23.

Boston Scientific Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.